Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record.

Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial

Open access
Räber, Lorenz, Wohlwend, Lea, Wigger, Mathias, Togni, Mario, Wandel, Simon, Wenaweser, Peter, Cook, Stéphane, Moschovitis, Aris, Vogel, Rolf, Kalesan, Bindu, Seiler, Christian, Eberli, Franz, Lüscher, Thomas F., Meier, Bernhard, Jüni, Peter, Windecker, Stephan·2011·Circulation

Abstract

Background—: Long-term comparative data of first-generation drug-eluting stents are scarce. We investigated clinical and angiographic outcomes of sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) at 5 years as part of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) LATE study. Methods and Results—: A total of 1012 patients were randomly assigned to SES or PES. Repeat angiography was completed in 444 of 1012 patients (43.8%) at 5 years. Major adverse cardiac events occurred in 19.7% of SES- and 21.4% of PES-treated patients (hazard ratio, 0.89; 95% confidence interval, 0.68 to 1.17; P =0.39) at 5 years. There were no differences between SES and PES in terms of cardiac death (5.8% versus 5.7%; P =0.35), myocardial infarction (6.6% versus 6.9%; P =0.51), and target lesion revascularization (13.1% versus 15.1%; P =0.29). Between 1 and 5 years, the annual rate of target lesion revascularization was 2.0% (95% confidence interval, 1.4% to 2.6%) for SES and 1.4% (95% confidence interval, 0.9% to 2.0%) for PES. Among patients undergoing paired angiography at 8 months and 5 years, delayed lumen loss amounted to 0.37±0.73 mm for SES and 0.29±0.59 mm for PES ( P =0.32). The overall rate of definite stent thrombosis was 4.6% for SES and 4.1% for PES ( P =0.74), and very late definite stent thrombosis occurred at an annual rate of 0.65% (95% confidence interval, 0.40% to 0.90%). Conclusions—: Long-term follow-up of first-generation drug-eluting stents shows no significant differences in clinical and angiographic outcomes between SES and PES. The continuous increase in late lumen loss in conjunction with the ongoing risk of very late stent thrombosis suggests that vascular healing remains incomplete up to 5 years after implantation of first-generation drug-eluting stents. Clinical Trial Registration—: http://www.clinicaltrials.gov . Unique identifier: NCT00297661.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.110.004762

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 186

Metadata

Authors
Räber, L., Wohlwend, L., Wigger, M., Togni, M., Wandel, S., Wenaweser, P., Cook, S., Moschovitis, A., Vogel, R., Kalesan, B., Seiler, C., Eberli, F., Lüscher, T. F., Meier, B., Jüni, P., & Windecker, S.
Venue
Circulation
Published
2011-06-21
Volume
123
Issue
24
Pages
2819-2828
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1976886356
Cited by
186
References
0
FWCI
29.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial. https://app.cochat.ai/papers/10.1161/circulationaha.110.004762
The paper
Räber, L., Wohlwend, L., Wigger, M., Togni, M., Wandel, S., Wenaweser, P., Cook, S., Moschovitis, A., Vogel, R., Kalesan, B., Seiler, C., Eberli, F., Lüscher, T. F., Meier, B., Jüni, P., & Windecker, S. (2011). Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial. Circulation. https://doi.org/10.1161/circulationaha.110.004762

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.